Compare DNTH & RDNT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DNTH | RDNT |
|---|---|---|
| Founded | 2015 | 1985 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical Specialities |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.9B | 5.5B |
| IPO Year | 2018 | 1996 |
| Metric | DNTH | RDNT |
|---|---|---|
| Price | $82.19 | $72.99 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 18 | 8 |
| Target Price | ★ $139.06 | $94.63 |
| AVG Volume (30 Days) | ★ 864.5K | 481.8K |
| Earning Date | 11-13-2026 | 11-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $2,036,000.00 | ★ $1,616,630,000.00 |
| Revenue This Year | N/A | $22.90 |
| Revenue Next Year | N/A | $12.36 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 13.05 |
| 52 Week Low | $32.28 | $50.82 |
| 52 Week High | $117.88 | $85.84 |
| Indicator | DNTH | RDNT |
|---|---|---|
| Relative Strength Index (RSI) | 45.45 | 55.96 |
| Support Level | $81.16 | $66.67 |
| Resistance Level | $91.36 | $78.97 |
| Average True Range (ATR) | 3.97 | 2.22 |
| MACD | 1.46 | 0.56 |
| Stochastic Oscillator | 80.52 | 72.35 |
Dianthus Therapeutics Inc. is a clinical-stage biotechnology company dedicated to developing potentially best-in-class therapies for patients with severe autoimmune diseases. The company operates as a single segment and has one reportable segment, focusing on creating next-generation treatments to revolutionize the management of severe autoimmune conditions. The team comprises experienced biotech and pharma executives. The pipeline includes the potential of Claseprubart, a next-generation complement therapeutic.
RadNet Inc is a national provider of diagnostic imaging services that operates in two business segments: Imaging Center segment and Digital Health segment. The Imaging Center segment provides physicians with imaging capabilities to facilitate the diagnosis and treatment of diseases and disorders. Services include magnetic resonance imaging (MRI), computed tomography (CT), positron emission tomography (PET), nuclear medicine, mammography, ultrasound, diagnostic radiology (X-ray), and fluoroscopy. The Digital Health segment develops and deploys clinical applications to enhance the interpretation of medical images and improve patient outcomes with an emphasis on brain, breast, prostate, and pulmonary diagnostic.